Life-saving drug to be rolled out in Africa within weeks, targeting children under 4.5kg
In a landmark breakthrough for global child health, a malaria treatment tailored specifically for babies and newborns has been approved for use. The drug—known as Coartem Baby—will be distributed across malaria-affected regions, especially in sub-Saharan Africa, in the coming weeks.
Until now, infants under 4.5kg (10lbs) were treated using medicines meant for older children, risking overdose and liver complications. This approval addresses what experts have called a “treatment gap” for the youngest and most vulnerable malaria patients.
Malaria still kills nearly 600,000 annually
According to 2023 data, malaria caused 597,000 deaths globally, with three-quarters of victims being children under five. Despite the availability of anti-malarial drugs for older children and adults, babies lacked a safe and approved treatment option until now.
The newly approved drug was developed by Novartis in collaboration with Medicines for Malaria Venture (MMV). It has been approved by Swiss regulators and will be offered on a not-for-profit basis in low-income countries.
“We are proud to have developed the first clinically proven malaria treatment for newborns,” said Novartis CEO Vas Narasimhan. “Even the smallest and most vulnerable can finally receive the care they deserve.”
A global partnership to protect the most vulnerable
The new pediatric formulation—also known as Riamet Baby in some countries—was tested in eight African countries, which are expected to be the first beneficiaries of the rollout.
Dr. Marvelle Brown, a public health expert, emphasized the impact on global equity:
“This drug can significantly reduce malaria deaths, especially in babies with sickle cell disease, who are particularly vulnerable due to weak immune systems.”
MMV’s Martin Fitchet added that this milestone strengthens the global arsenal to defeat malaria:
“With the right tools and resources, malaria can be eliminated. Coartem Baby adds a vital weapon to that fight.”
What’s next?
The rollout of Coartem Baby marks a critical step forward in the decades-long fight against malaria. Health officials hope this will lower infant mortality rates and reduce healthcare inequality in the hardest-hit regions.
First malaria treatment for babies approved for use
Trump meets five African presidents this week
